Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>With pathway‐specific trials in PD associated with variants in the glucocerebrosidase gene (PD<sub>GBA</sub>) under way, we need markers that confirm the impact of genetic variants in patient‐derived biofluids in order to allow patient stratification merely based on genetics and that might serve as biochemical read‐out for target engagement. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To explore GBA‐pathway‐specific biomarker profiles cross‐sectionally (TUEPAC‐MIGAP, PPMI) and longitudinally (PPMI).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We measured enzyme activity of the lysosomal glucocerebrosidase, CSF levels of glucosylceramides (upstream substrate of glucocerebrosidase), CSF levels of ceramides (downstream product of glucocerebrosidase), lactosylceramides, sphingosines, sphingomyelin (by‐products) and CSF levels of total α‐synuclein in PD<sub>GBA</sub> patients compared to PD<sub>GBA_wildtype</sub> patients. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Cross‐sectionally in both cohorts and longitudinally in PPMI: (1) glucocerebrosidase activity was significantly lower in PD<sub>GBA</sub> compared to PD<sub>GBA_wildtype</sub>. (2) CSF levels of upstream substrates (glucosylceramides species) were higher in PD<sub>GBA</sub> compared to PD<sub>GBA_wildtype</sub>. (3) CSF levels of total α‐synuclein were lower in PD<sub>GBA</sub> compared to PD<sub>GBA_wildtype</sub>. All of these findings were most pronounced in PD<sub>GBA</sub> with severe mutations (PD<sub>GBA_severe</sub>). Cross‐sectionally in TUEPAC‐MIGAP and longitudinally in PPMI, CSF levels of downstream‐products (ceramides) were higher in PD<sub>GBA_severe</sub>. Cross‐sectionally in TUEPAC‐MIGAP by‐products sphinganine and sphingosine‐1‐phosphate and longitudinally in PPMI species of by‐products lactosylceramides and sphingomyelin were higher in PD<sub>GBA_severe</sub>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>These findings confirm that GBA mutations have a relevant functional impact on biomarker profiles in patients. Bridging the gap between genetics and biochemical profiles now allows patient stratification for clinical trials merely based on mutation status. Importantly, all findings were most prominent in PD<sub>GBA</sub> with severe variants. © 2021 International Parkinson and Movement Disorder Society </p></section>

Peripheral Upregulation of Parkinson's Disease-Associated Genes Encoding α-Synuclein, β-Glucocerebrosidase, and Ceramide Glucosyltransferase in Major Depression

Increased Ratio of Mature BDNF to Precursor-Bdnf in Patients with Major Depressive Disorder with Severe Anhedonia.

Identification and Experimental Validation of Parkinson’s Disease with Major Depressive Disorder Common Genes

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Unraveling the transcriptomic signatures of Parkinson's disease and major depression using single-cell and bulk data

Mir-218-5p and Mir-320A-5p As Biomarkers for Brain Disorders: Focus on the Major Depressive Disorder and Parkinson's Disease.

Brain Region-Specific Expression Levels of Synuclein Genes in an Acid Sphingomyelinase Knockout Mouse Model: Correlation with Depression-/Anxiety-Like Behavior and Locomotor Activity in the Absence of Genotypic Variation

GABAergic imbalance in Parkinson's disease-related depression determined with MEGA-PRESS

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients.

Cognition, motor symptoms, and glycolipid metabolism in Parkinson’s disease with depressive symptoms

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI

Gene Expression Signatures Differentiating Major Depressive Disorder from Subsyndromal Symptomatic Depression.

Dysregulation of synaptic-related genes within neuroimmune networks of peripheral blood mononuclear cells in major depressive disorder

Key Risk Genes Identified From the Postmortem Brain of Patients With Major Depressive Disorder and Their Potential Clinical Applications

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA

Integrative analysis of gene expression profiles of substantia nigra identifies potential diagnosis biomarkers in Parkinson's disease

Identification of Key Genes and the Pathophysiology Associated with Major Depressive Disorder Patients Based on Integrated Bioinformatics Analysis

Identification of novel endoplasmic reticulum-related genes and their association with immune cell infiltration in major depressive disorder

Sex-dependent associations of serum BDNF, glycolipid metabolism and cognitive impairments in Parkinson's disease with depression: a comprehensive analysis